AKRO - Akero Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Akero Therapeutics, Inc.

601 Gateway Boulevard
Suite 350
South San Francisco, CA 94080
United States
650 487 6488

Full Time Employees41

Key Executives

NameTitlePayExercisedYear Born
Dr. Andrew Cheng M.D., Ph.D.Pres, CEO & Director1.22M4.86M1967
Dr. Jonathan M. Young J.D., Ph.D.Co-Founder, Exec. VP, COO & Sec.763.3k1.56M1970
Dr. Timothy RolphCo-Founder & Chief Scientific Officer819.4k1.3M1954
Mr. William R. White J.D.Exec. VP, CFO, Treasurer & Head of Corp. Devel.768.4k2.31M1973
Ms. Catriona YaleExec. VP & Chief Devel. Officer754.8kN/A1972
Mr. Patrick LamySr. VP of Commercial StrategyN/AN/A1973
Mr. John J. SchembriVP of Fin. & ControllerN/AN/A1962
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Corporate Governance

Akero Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2023 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.